Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Acquired Immunodeficiency Syndrome

Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Andersen JW, Fass R, van der Horst C. "Factors associated with early study discontinuation in AACTG studies, DACS 200." Contemp Clin Trials. 2007;28(5):583-92.
Dykes C, A Mukherjee L, Bosch RJ, Connick E, Volberding PA, Demeter LM. "Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371." J. Acquir. Immune Defic. Syndr.. 2010;55(1):132-4.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Grady BJ, Samuels DC, Robbins GK, et al. "Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384." J. Acquir. Immune Defic. Syndr.. 2011;58(4):363-70.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.

Adenine

Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Vogler MA, Smeaton LM, Wright RL, et al. "Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227." J. Acquir. Immune Defic. Syndr.. 2014;65(5):542-50.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Parikh UM, Bacheler L, Koontz D, Mellors JW. "The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations." J. Virol.. 2006;80(10):4971-7.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.

Pages